10 October 2018 - Deborah Wilkes
A chief digital officer will be part of Albert Bourla's executive leadership team when he becomes Pfizer's chief executive officer on 1 January 2019.
Pfizer has recruited Lidia Fonseca, who is currently chief information officer and senior vice president at Quest Diagnostics, to fill the new post of executive vice president, chief digital and technology officer. Fonseca has also worked for Synarc and Philips Healthcare.
Fonseca will be responsible for creating and implementing a strategy that "accelerates and improves" Pfizer's digital capabilities.
Commenting on its reasons for creating the new role, Pfizer highlighted the "growing strategic importance of deploying digital technologies in research, discovery and business processes".
Fonseca's appointment is part of a wider reorganisation of Pfizer's executive leadership team from 1 January 2019.
Pfizer recently announced that Bourla, who is its chief operating officer, would replace Ian Read as chief executive officer from 1 January 2019 (click here to read the News story).
Strategic review for Consumer Healthcare
Pfizer is evaluating strategic alternatives for its Consumer Healthcare business including spin-offs and joint ventures.
Bourla said recently that Pfizer would make a decision about the future of its Consumer Healthcare business by the end of 2018 (click here to read the News story).
Pfizer announced on 10 October 2017 that it was considering a range of strategic alternatives, including divestment, for its global Consumer Healthcare business.
The pharmaceutical company said in a statement that it would consider a range of options including “a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction”. Pfizer noted that it might “ultimately determine to retain the business”.
In May 2018, Read said the company had "not received an acceptable offer" for the sale of its Consumer Healthcare business.
Read added that the company would continue to explore everything from a full or partial separation of Consumer Healthcare through to retaining the business. He noted that Pfizer would look at potential spin-offs or joint ventures.
Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE